Release clinical data for EPP and XLP trials
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Dec 2023
- Due
- 31 Mar 2024
- Delivered
- April 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Today’s Focus Data Early 2024 EPP and XLP”
What we found
Evidence strength A What the grades mean
The company announced topline data for the AURORA trial in April 2024, which occurred after the 'early 2024' deadline.
-
A Disc Medicine, Inc. 10-Q filed 2024-05-09
“we presented topline data from AURORA in April 2024.” ✓ confirmed on the page
Market reaction: the shares moved +5.0% against the S&P 500 over the three sessions around the disclosure (8 May 2024 to 13 May 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Release
- Deliverable
- EPP and XLP clinical trial data
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-IRON-002156 · Corrections policy